Efficacy of vericiguat in patients with chronic heart failure and reduced ejection fraction: a prospective observational study.

IF 2.3 3区医学 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS BMC Cardiovascular Disorders Pub Date : 2025-02-05 DOI:10.1186/s12872-025-04477-2

Yinge Zhan, Liu Li, Jie Zhou, Yishan Ma, Xuchong Guan, Suo Wang, Ya Chang

{"title":"Efficacy of vericiguat in patients with chronic heart failure and reduced ejection fraction: a prospective observational study.","authors":"Yinge Zhan, Liu Li, Jie Zhou, Yishan Ma, Xuchong Guan, Suo Wang, Ya Chang","doi":"10.1186/s12872-025-04477-2","DOIUrl":null,"url":null,"abstract":"Objectives: This study aims to evaluate the therapeutic effect of Vericiguat through cardiopulmonary exercise testing (CPET) in patients with chronic heart failure and reduced ejection fraction (HFrEF).Methods: A prospective observational study was conducted from May 2022 to May 2023, focusing on patients with HFrEF admitted to our hospital. Eligible patients were sequentially numbered and enrolled based on specific inclusion and exclusion criteria. They were divided into two groups: one receiving standard heart failure therapy and the other receiving standard therapy plus Vericiguat. Data were collected at baseline and at 1, 3, and 6 months post-discharge, including NT-proBNP, sST2, and echocardiographic assessments. All patients underwent CPET before discharge and again six months post-discharge for within-subject comparisons.Results: The study enrolled 158 patients, with 79 in each treatment arm. No significant baseline differences were observed in the Weber Functional Classification or CPET parameters. At six months, the Vericiguat group exhibited a significant reduction in patients classified as C (from 31.6 to 7.5%) and D (from 31.6 to 3.7%), with P values less than 0.05. Additionally, Vericiguat significantly improved Peak Oxygen Consumption (from 14.24 ± 6.21 to 19.03 ± 4.87 ml/kg/min) and Anaerobic Threshold (from 10.48 ± 3.82 to 13.48 ± 3.31 ml/kg/min). Compared to the standard treatment group, the Vericiguat group demonstrated significantly higher Peak Oxygen Consumption, Anaerobic Threshold, and a lower Carbon Dioxide Equivalent Slope, with P values all below 0.05.Conclusions: Vericiguat safely enhances exercise tolerance, as evaluated by CPET, in high-risk patients with HFrEF.","PeriodicalId":9195,"journal":{"name":"BMC Cardiovascular Disorders","volume":"25 1","pages":"83"},"PeriodicalIF":2.3000,"publicationDate":"2025-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11796121/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMC Cardiovascular Disorders","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12872-025-04477-2","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives: This study aims to evaluate the therapeutic effect of Vericiguat through cardiopulmonary exercise testing (CPET) in patients with chronic heart failure and reduced ejection fraction (HFrEF).

Methods: A prospective observational study was conducted from May 2022 to May 2023, focusing on patients with HFrEF admitted to our hospital. Eligible patients were sequentially numbered and enrolled based on specific inclusion and exclusion criteria. They were divided into two groups: one receiving standard heart failure therapy and the other receiving standard therapy plus Vericiguat. Data were collected at baseline and at 1, 3, and 6 months post-discharge, including NT-proBNP, sST2, and echocardiographic assessments. All patients underwent CPET before discharge and again six months post-discharge for within-subject comparisons.

Results: The study enrolled 158 patients, with 79 in each treatment arm. No significant baseline differences were observed in the Weber Functional Classification or CPET parameters. At six months, the Vericiguat group exhibited a significant reduction in patients classified as C (from 31.6 to 7.5%) and D (from 31.6 to 3.7%), with P values less than 0.05. Additionally, Vericiguat significantly improved Peak Oxygen Consumption (from 14.24 ± 6.21 to 19.03 ± 4.87 ml/kg/min) and Anaerobic Threshold (from 10.48 ± 3.82 to 13.48 ± 3.31 ml/kg/min). Compared to the standard treatment group, the Vericiguat group demonstrated significantly higher Peak Oxygen Consumption, Anaerobic Threshold, and a lower Carbon Dioxide Equivalent Slope, with P values all below 0.05.

Conclusions: Vericiguat safely enhances exercise tolerance, as evaluated by CPET, in high-risk patients with HFrEF.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

vericiguat对慢性心力衰竭和射血分数降低患者的疗效：一项前瞻性观察研究。

目的：通过心肺运动试验（CPET）评价Vericiguat对慢性心力衰竭并射血分数降低（HFrEF）患者的治疗效果。方法：于2022年5月至2023年5月对我院收治的HFrEF患者进行前瞻性观察性研究。根据特定的纳入和排除标准，对符合条件的患者进行顺序编号和入组。他们被分为两组：一组接受标准心力衰竭治疗，另一组接受标准治疗加Vericiguat。在基线和出院后1、3和6个月收集数据，包括NT-proBNP、sST2和超声心动图评估。所有患者在出院前和出院后6个月再次接受CPET进行受试者内比较。结果：该研究纳入了158例患者，每个治疗组79例。在韦伯功能分类或CPET参数中没有观察到显著的基线差异。6个月时，Vericiguat组C级（从31.6降至7.5%）和D级（从31.6降至3.7%）患者显著减少，P值小于0.05。此外，Vericiguat显著提高了峰值耗氧量（从14.24±6.21 ml/kg/min到19.03±4.87 ml/kg/min）和厌氧阈（从10.48±3.82 ml/kg/min到13.48±3.31 ml/kg/min）。与标准治疗组相比，Vericiguat组的峰值耗氧量、厌氧阈值显著升高，二氧化碳当量斜率显著降低，P值均小于0.05。结论：根据CPET评估，Vericiguat可安全地提高HFrEF高危患者的运动耐量。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

BMC Cardiovascular Disorders CARDIAC & CARDIOVASCULAR SYSTEMS-

CiteScore

3.50

自引率

0.00%

发文量

480

审稿时长

1 months

期刊介绍： BMC Cardiovascular Disorders is an open access, peer-reviewed journal that considers articles on all aspects of the prevention, diagnosis and management of disorders of the heart and circulatory system, as well as related molecular and cell biology, genetics, pathophysiology, epidemiology, and controlled trials.